Access
To read this story in full you will need to login or make a payment (see right).
Letter
Nature Medicine 14, 676 - 680 (2008)
Published online: 11 May 2008 | doi:10.1038/nm1769
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Roberto Chiarle1,2, Cinzia Martinengo1,5, Cristina Mastini1,3,5, Chiara Ambrogio1,2, Valentina D'Escamard4, Guido Forni3 & Giorgio Inghirami1,2,4
Abstract
An ideal vaccination strategy against tumors relies on specific antigens that are required for tumor maintenance1. For lymphoma, vaccination with subject-specific immunoglobulin idiotypes has had the most promising results2, 3. Here we show that DNA vaccination with plasmids encoding portions of the cytoplasmic domain of anaplastic lymphoma kinase (ALK), which has been translocated in different fusion proteins necessary for the growth of anaplastic large cell lymphoma (ALCL)4, protects mice from local and systemic lymphoma growth. The protection is potent and long lasting and elicits ALK-specific interferon-
responses and CD8+ T cell–mediated cytotoxicity. A combination of chemotherapy and vaccination significantly enhanced the survival of mice challenged with ALK+ lymphomas. These findings indicate that ALK represents an ideal tumor antigen for vaccination-based therapies of ALCL and possibly other ALK+ human tumors4, 5, 6, 7.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNature Medicine Article (01 Jun 2005)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature Letters to Editor (16 Oct 2008)
Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomasOncogene Scientific Correspondence
See all 35 matches for Research